Atlas Trials

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Clinical trial NCT04915950 · TERMINATED

Trial details

NCT number
NCT04915950
Sponsor
Pfizer
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Start date
2021-11-03
Primary completion
2022-09-02
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.